Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway

British Journal of Pharmacology

Volumn 170, Issue 4, 2013, Pages 871-882

  Martínez, Sandra ^a,b   Pérez, Laura ^a   Galmarini, Carlos M ^b   Aracil, Miguel ^b   Tercero, Juan C ^b   Gago, Federico ^c   Albella, Beatriz ^a   Bueren, Juan A ^a  

^a CIEMAT   (Spain)

^b PHARMAMAR S A   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

anti cancer drugs; DNA damage; DNA inter strand cross linking drugs; Fanconi anaemia; PM01183; trabectedin; Zalypsis

Indexed keywords

DNA; FANCONI ANEMIA PROTEIN; LURBINECTEDIN; MITOMYCIN; PM 00104; TETRAHYDROISOQUINOLINE DERIVATIVE; TRABECTEDIN; UNCLASSIFIED DRUG; ZALYPSIS;

ANIMAL CELL; ARTICLE; CANCER CELL; CELL TRANSFORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; DNA CROSS LINKING; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANTI-CANCER DRUGS; DNA DAMAGE; DNA INTER-STRAND CROSS-LINKING DRUGS; FANCONI ANAEMIA; PM01183; TRABECTEDIN; ZALYPSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CARBOLINES; CELL LINE, TUMOR; DIOXOLES; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MICE; MICE, 129 STRAIN; MICE, INBRED BALB C; MICE, TRANSGENIC; MITOMYCIN; NEOPLASMS; SIGNAL TRANSDUCTION; TETRAHYDROISOQUINOLINES;

EID: 84885159110     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12331     Document Type: Article

References (48)

1. Berenbaum MC, (1989). What is synergy? Pharmacol Rev 41: 93-141.
2. Bogliolo M, Schuster B, Stoepker C, Derkunt B, Su Y, Raams A, et al. (2013). Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am J Hum Genet 92: 800-806.
3. Bueren-Calabuig JA, Giraudon C, Galmarini CM, Egly JM, Gago F, (2011). Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations. Nucleic Acids Res 39: 8248-8257.
4. Bueren-Calabuig JA, Negri A, Morreale A, Gago F, (2012). Rationale for the opposite stereochemistry of the major monoadducts and interstrand crosslinks formed by mitomycin C and its decarbamoylated analogue at CpG steps in DNA and the effect of cytosine modification on reactivity. Org Biomol Chem 10: 1543-1552.
5. Casado JA, Callen E, Jacome A, Rio P, Castella M, Lobitz S, et al. (2007). A comprehensive strategy for the subtyping of Fanconi anemia patients: conclusions from the Spanish Fanconi anemia research network. J Med Genet 44: 241-249.
6. Casado JA, Rio P, Marco E, Garcia-Hernandez V, Domingo A, Perez L, et al. (2008). Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther 7: 1309-1318.
7. Cheng NC, van de Vrugt HJ, van der Valk MA, Oostra AB, Krimpenfort P, de Vries Y, et al. (2000). Mice with a targeted disruption of the Fanconi anemia homolog Fanca. Hum Mol Genet 9: 1805-1811.
8. Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, et al. (2006). Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 5: 952-961.
9. Colado E, Paino T, Maiso P, Ocio EM, Chen X, Alvarez-Fernandez S, et al. (2011). Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica 96: 687-695.
10. D'Incalci M, Galmarini CM, (2010). A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 9: 2157-2163.
11. David-Cordonnier MH, Gajate C, Olmea O, Laine W, de la Iglesia-Vicente J, Perez C, et al. (2005). DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem Biol 12: 1201-1210.
12. Fayette J, Coquard IR, Alberti L, Boyle H, Meeus P, Decouvelaere AV, et al. (2006). ET-743: a novel agent with activity in soft-tissue sarcomas. Curr Opin Oncol 18: 347-353.
13. Feuerhahn S, Giraudon C, Martinez-Diez M, Bueren-Calabuig JA, Galmarini CM, Gago F, et al. (2011). XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids. Chem Biol 18: 988-999.
14. Gago F, Hurley LH, (2002). Devising a structural basis for the potent cytotoxic effects of ecteinascidin 743. In:, Demeunynck M, Bailly C, Wilson WD, (eds). Small Molecule DNA and RNA Binders: From Synthesis to Nucleic Acid Complexes. Wiley-VCH: Weinheim, Germany, pp. 643-675.
15. Guirouilh-Barbat J, Antony S, Pommier Y, (2009). Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition. Mol Cancer Ther 8: 2007-2014.
16. Hanenberg H, Batish SD, Pollok KE, Vieten L, Verlander PC, Leurs C, et al. (2002). Phenotypic correction of primary Fanconi anemia T cells with retroviral vectors as a diagnostic tool. Exp Hematol 30: 410-420.
17. van der Heijden MS, Brody JR, Gallmeier E, Cunningham SC, Dezentje DA, Shen D, et al. (2004). Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 165: 651-657.
18. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S, (2006). Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 66: 8155-8162.
19. Hess CJ, Ameziane N, Schuurhuis GJ, Errami A, Denkers F, Kaspers GJ, et al. (2008). Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. Cell Oncol 30: 299-306.
20. Jin S, Gorfajn B, Faircloth G, Scotto KW, (2000). Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A 97: 6775-6779.
21. Kachnic LA, Li L, Fournier L, Ferraiolo N, Dahm-Daphi J, Borgmann K, et al. (2011). FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons. Cancer Lett 305: 86-93.
22. Kee Y, D'Andrea AD, (2010). Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev 24: 1680-1694.
23. Kee Y, D'Andrea AD, (2012). Molecular pathogenesis and clinical management of Fanconi anemia. J Clin Invest 122: 3799-3806.
24. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
25. Knipscheer P, Raschle M, Smogorzewska A, Enoiu M, Ho TV, Scharer OD, et al. (2009). The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science 326: 1698-1701.
26. Koul S, McKiernan JM, Narayan G, Houldsworth J, Bacik J, Dobrzynski DL, et al. (2004). Role of promoter hypermethylation in cisplatin treatment response of male germ cell tumors. Mol Cancer 3: 16.
27. Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF, et al. (2003). A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101: 1249-1256.
28. Leal JF, Garcia-Hernandez V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, et al. (2009). Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines. Biochem Pharmacol 78: 162-170.
29. Leal JF, Martinez-Diez M, Garcia-Hernandez V, Moneo V, Domingo A, Bueren-Calabuig JA, et al. (2010). PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol 161: 1099-1110.
30. Lyakhovich A, Surralles J, (2006). Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer. Cancer Lett 232: 99-106.
31. McAllister KA, Bennett LM, Houle CD, Ward T, Malphurs J, Collins NK, et al. (2002). Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene. Cancer Res 62: 990-994.
32. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
33. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT, (2004). Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23: 1000-1004.
34. Martinez N, Sanchez-Beato M, Carnero A, Moneo V, Tercero JC, Fernandez I, et al. (2005). Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther 4: 814-823.
35. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R, (2000). Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A 97: 6780-6784.
36. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, et al. (2012). Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer 48: 2361-2368.
37. Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernandez S, San-Segundo L, et al. (2009). Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood 113: 3781-3791.
38. Palagyi A, Neveling K, Plinninger U, Ziesch A, Targosz BS, Denk GU, et al. (2010). Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents. Mol Cancer 9: 127.
39. Pessina A, Albella B, Bueren J, Brantom P, Casati S, Gribaldo L, et al. (2001). Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. Toxicol In Vitro 15: 729-740.
40. Soares DG, Escargueil AE, Poindessous V, Sarasin A, de Gramont A, Bonatto D, et al. (2007). Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A 104: 13062-13067.
41. Soares DG, Machado MS, Rocca CJ, Poindessous V, Ouaret D, Sarasin A, et al. (2011). Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells. Mol Cancer Ther 10: 1481-1489.
42. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, et al. (2003). Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9: 568-574.
43. Valeri A, Martinez S, Casado JA, Bueren JA, (2011). Fanconi anaemia: from a monogenic disease to sporadic cancer. Clin Transl Oncol 13: 215-221.
44. Vidal A, Munoz C, Guillen MJ, Moreto J, Sara P, Martinez-Iniesta M, et al. (2012). Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin Cancer Res 18: 5399-5411.
45. Williams G, (1992). Comments on Miaskowski et al., Pain 49 (1992) 137-144. Pain 51: 383-387.
46. Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, et al. (2009). Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res 69: 9367-9375.
47. van Zeeburg HJ, Snijders PJ, Pals G, Hermsen MA, Rooimans MA, Bagby G, et al. (2005). Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients. Cancer Res 65: 1271-1276.
48. Zhang J, Zhao D, Park HK, Wang H, Dyer RB, Liu W, et al. (2010). FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth. J Clin Invest 120: 1524-1534.